Symbols / OGN Stock $13.32 +1.22% Organon & Co.

Healthcare • Drug Manufacturers - General • United States • NYQ
OGN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - General
CEO Mr. Joseph T. Morrissey Jr.
Exch · Country NYQ · United States
Market Cap 3.50B
Enterprise Value 11.69B
Income 187.00M
Sales 6.22B
FCF (ttm) 190.12M
Book/sh 2.89
Cash/sh 2.21
Employees 10,000
Insider 10d —
IPO May 14, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 47.22%
P/E 18.50
Forward P/E 3.61
PEG —
P/S 0.56
P/B 4.61
P/C —
EV/EBITDA 7.07
EV/Sales 1.88
Quick Ratio 0.84
Current Ratio 1.82
Debt/Eq 1,170.21
LT Debt/Eq —
EPS (ttm) 0.72
EPS next Y 3.69
EPS Growth —
Revenue Growth -5.30%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-02-12
ROA 6.22%
ROE 30.56%
ROIC —
Gross Margin 54.34%
Oper. Margin 16.19%
Profit Margin 3.01%
Shs Outstand 262.60M
Shs Float 258.73M
Insider Own 0.40%
Instit Own 76.81%
Short Float 9.52%
Short Ratio 2.86
Short Interest 18.61M
52W High 13.38
vs 52W High -0.42%
52W Low 5.69
vs 52W Low 134.09%
Beta 0.64
Impl. Vol. 1.56%
Rel Volume 4.15
Avg Volume 8.47M
Volume 35.14M
Target (mean) $8.60
Tgt Median $9.00
Tgt Low $5.00
Tgt High $12.00
# Analysts 5
Recom Hold
Prev Close $13.16
Price $13.32
Change 1.22%
About

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.60
Mean price target
2. Current target
$13.32
Latest analyst target
3. DCF / Fair value
$13.03
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.32
Low
$5.00
High
$12.00
Mean
$8.60

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-28 up Piper Sandler Underweight → Neutral $14
2026-02-24 main Barclays Underweight → Underweight $8
2025-12-09 init Barclays — → Underweight $8
2025-11-11 main JP Morgan Underweight → Underweight $12
2025-11-11 main Morgan Stanley Equal-Weight → Equal-Weight $9
2025-05-15 main Piper Sandler Overweight → Overweight $18
2025-05-05 main Morgan Stanley Equal-Weight → Equal-Weight $10
2025-04-09 main Morgan Stanley Equal-Weight → Equal-Weight $15
2025-02-14 main Barclays Overweight → Overweight $24
2025-02-14 main Morgan Stanley Equal-Weight → Equal-Weight $16
2024-09-06 down JP Morgan Neutral → Underweight $20
2024-05-06 main Goldman Sachs Neutral → Neutral $20
2024-05-03 main Goldman Sachs Neutral → Neutral $20
2024-04-29 main Piper Sandler Overweight → Overweight $24
2024-02-20 main Goldman Sachs Neutral → Neutral $18
2023-11-22 main Piper Sandler Overweight → Overweight $22
2023-11-03 down Goldman Sachs Buy → Neutral $16
2023-10-25 main Piper Sandler Overweight → Overweight $32
2023-10-11 main Morgan Stanley Equal-Weight → Equal-Weight $22
2023-09-21 init Barclays — → Overweight $28
News
RSS: Latest OGN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-31 WALSH MATTHEW M Chief Financial Officer — 33,593 — —
2026-03-31 ARJONA FERREIRA JUAN CAMILO Officer — 13,431 — —
2026-03-31 KARP DANIEL Officer — 18,053 — —
2026-03-31 STAHLER RACHEL A Chief Technology Officer — 18,867 — —
2026-03-31 MORRISSEY JOSEPH T JR Chief Executive Officer — 24,584 — —
2026-03-31 FALCIONE AARON Officer — 17,925 — —
2026-03-31 NISITA VITTORIO Officer — 13,000 — —
2026-03-31 WEAVER KIRKE General Counsel — 18,513 — —
2026-03-31 HOLZBAUR LYNETTE Officer — 10,967 — —
2026-03-31 DRINANE JULIANA PAPA Officer — 16,451 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
6,216.00
-2.92%
6,403.00
+2.24%
6,263.00
+1.44%
6,174.00
Operating Revenue
6,216.00
-2.92%
6,403.00
+2.24%
6,263.00
+1.44%
6,174.00
Cost Of Revenue
2,903.00
+8.00%
2,688.00
+6.88%
2,515.00
+9.63%
2,294.00
Reconciled Cost Of Revenue
2,903.00
+8.00%
2,688.00
+6.88%
2,515.00
+9.63%
2,294.00
Gross Profit
3,313.00
-10.82%
3,715.00
-0.88%
3,748.00
-3.40%
3,880.00
Operating Expense
2,087.00
-6.37%
2,229.00
-7.93%
2,421.00
+11.31%
2,175.00
Research And Development
366.00
-21.96%
469.00
-11.17%
528.00
+12.10%
471.00
Selling General And Administration
1,721.00
-2.22%
1,760.00
-7.03%
1,893.00
+11.09%
1,704.00
Total Expenses
4,990.00
+1.48%
4,917.00
-0.38%
4,936.00
+10.45%
4,469.00
Operating Income
1,226.00
-17.50%
1,486.00
+11.98%
1,327.00
-22.17%
1,705.00
EBITDA
1,290.00
-19.58%
1,604.00
+11.70%
1,436.00
-18.22%
1,756.00
Normalized EBITDA
1,706.00
-2.07%
1,742.00
+12.53%
1,548.00
-18.61%
1,902.00
Reconciled Depreciation
361.00
+30.32%
277.00
+17.37%
236.00
+11.32%
212.00
EBIT
929.00
-29.99%
1,327.00
+10.58%
1,200.00
-22.28%
1,544.00
Total Unusual Items
-416.00
-201.45%
-138.00
-23.21%
-112.00
+23.29%
-146.00
Total Unusual Items Excluding Goodwill
-416.00
-201.45%
-138.00
-23.21%
-112.00
+23.29%
-146.00
Special Income Charges
-402.00
-258.93%
-112.00
-60.00%
-70.00
+48.15%
-135.00
Other Special Charges
6.00
-92.59%
81.00
+912.50%
8.00
-92.52%
107.00
Impairment Of Capital Assets
301.00
0.00
0.00
—
Restructuring And Mergern Acquisition
95.00
+206.45%
31.00
-50.00%
62.00
+121.43%
28.00
Net Income
187.00
-78.36%
864.00
-15.54%
1,023.00
+11.56%
917.00
Pretax Income
425.00
-47.34%
807.00
+19.91%
673.00
-40.02%
1,122.00
Net Non Operating Interest Income Expense
-504.00
+3.08%
-520.00
+1.33%
-527.00
-24.88%
-422.00
Interest Expense Non Operating
504.00
-3.08%
520.00
-1.33%
527.00
+24.88%
422.00
Net Interest Income
-504.00
+3.08%
-520.00
+1.33%
-527.00
-24.88%
-422.00
Interest Expense
504.00
-3.08%
520.00
-1.33%
527.00
+24.88%
422.00
Other Income Expense
-297.00
-86.79%
-159.00
-25.20%
-127.00
+21.12%
-161.00
Other Non Operating Income Expenses
119.00
+666.67%
-21.00
-40.00%
-15.00
+0.00%
-15.00
Gain On Sale Of Security
-14.00
+46.15%
-26.00
+38.10%
-42.00
-281.82%
-11.00
Tax Provision
238.00
+517.54%
-57.00
+83.71%
-350.00
-270.73%
205.00
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+14.75%
0.00
Tax Effect Of Unusual Items
-87.36
-201.45%
-28.98
-23.21%
-23.52
+11.97%
-26.72
Net Income Including Noncontrolling Interests
187.00
-78.36%
864.00
-15.54%
1,023.00
+11.56%
917.00
Net Income From Continuing Operation Net Minority Interest
187.00
-78.36%
864.00
-15.54%
1,023.00
+11.56%
917.00
Net Income From Continuing And Discontinued Operation
187.00
-78.36%
864.00
-15.54%
1,023.00
+11.56%
917.00
Net Income Continuous Operations
187.00
-78.36%
864.00
-15.54%
1,023.00
+11.56%
917.00
Net Income Discontinuous Operations
—
—
0.00
0.00
Normalized Income
515.64
-47.01%
973.02
-12.46%
1,111.48
+7.26%
1,036.28
Net Income Common Stockholders
187.00
-78.36%
864.00
-15.54%
1,023.00
+11.56%
917.00
Diluted EPS
0.72
-78.38%
3.33
-16.54%
3.99
+11.14%
3.59
Basic EPS
0.72
-78.57%
3.36
-16.21%
4.01
+11.08%
3.61
Basic Average Shares
259.50
+0.95%
257.05
+0.71%
255.24
+0.46%
254.08
Diluted Average Shares
260.76
+0.62%
259.15
+1.12%
256.27
+0.43%
255.17
Diluted NI Availto Com Stockholders
187.00
-78.36%
864.00
-15.54%
1,023.00
+11.56%
917.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
12,867.00
-1.79%
13,101.00
+8.65%
12,058.00
+10.07%
10,955.00
Current Assets
4,352.00
+0.09%
4,348.00
-3.55%
4,508.00
+14.68%
3,931.00
Cash Cash Equivalents And Short Term Investments
574.00
-14.96%
675.00
-2.60%
693.00
-1.84%
706.00
Cash And Cash Equivalents
574.00
-14.96%
675.00
-2.60%
693.00
-1.84%
706.00
Receivables
1,331.00
-1.99%
1,358.00
-22.13%
1,744.00
+18.24%
1,475.00
Accounts Receivable
1,331.00
-1.99%
1,358.00
-22.13%
1,744.00
+18.24%
1,475.00
Gross Accounts Receivable
1,343.00
-2.11%
1,372.00
-21.73%
1,753.00
+18.13%
1,484.00
Allowance For Doubtful Accounts Receivable
-12.00
+14.29%
-14.00
-55.56%
-9.00
+0.00%
-9.00
Inventory
1,406.00
+6.43%
1,321.00
+0.46%
1,315.00
+31.11%
1,003.00
Assets Held For Sale Current
8.00
0.00
—
—
Other Current Assets
1,033.00
+3.92%
994.00
+31.48%
756.00
+1.20%
747.00
Total Non Current Assets
8,515.00
-2.72%
8,753.00
+15.93%
7,550.00
+7.49%
7,024.00
Net PPE
1,303.00
+11.56%
1,168.00
-1.27%
1,183.00
+16.21%
1,018.00
Gross PPE
2,542.00
+14.09%
2,228.00
+1.27%
2,200.00
+14.58%
1,920.00
Accumulated Depreciation
-1,239.00
-16.89%
-1,060.00
-4.23%
-1,017.00
-12.75%
-902.00
Properties
0.00
0.00
0.00
0.00
Land And Improvements
15.00
+25.00%
12.00
-14.29%
14.00
+7.69%
13.00
Buildings And Improvements
850.00
+17.89%
721.00
+0.00%
721.00
+3.89%
694.00
Machinery Furniture Equipment
1,388.00
+14.81%
1,209.00
+1.51%
1,191.00
+27.38%
935.00
Construction In Progress
289.00
+1.05%
286.00
+4.38%
274.00
-1.44%
278.00
Goodwill And Other Intangible Assets
5,283.00
-13.31%
6,094.00
+18.65%
5,136.00
-2.21%
5,252.00
Goodwill
4,153.00
-11.26%
4,680.00
+1.67%
4,603.00
+0.00%
4,603.00
Other Intangible Assets
1,130.00
-20.08%
1,414.00
+165.29%
533.00
-17.87%
649.00
Other Non Current Assets
1,929.00
+29.38%
1,491.00
+21.12%
1,231.00
+63.26%
754.00
Total Liabilities Net Minority Interest
12,115.00
-4.07%
12,629.00
+4.13%
12,128.00
+2.37%
11,847.00
Current Liabilities
2,390.00
-12.07%
2,718.00
-6.85%
2,918.00
+16.16%
2,512.00
Payables And Accrued Expenses
2,372.00
-12.08%
2,698.00
-7.25%
2,909.00
+16.17%
2,504.00
Payables
1,037.00
-19.43%
1,287.00
-15.33%
1,520.00
+15.50%
1,316.00
Accounts Payable
952.00
-17.43%
1,153.00
-12.25%
1,314.00
+16.08%
1,132.00
Current Accrued Expenses
1,335.00
-5.39%
1,411.00
+1.58%
1,389.00
+16.92%
1,188.00
Total Tax Payable
85.00
-36.57%
134.00
-34.95%
206.00
+11.96%
184.00
Income Tax Payable
85.00
-36.57%
134.00
-34.95%
206.00
+11.96%
184.00
Current Debt And Capital Lease Obligation
16.00
-20.00%
20.00
+122.22%
9.00
+12.50%
8.00
Current Debt
16.00
-20.00%
20.00
+122.22%
9.00
+12.50%
8.00
Other Current Borrowings
—
—
—
—
Other Current Liabilities
2.00
—
—
1,188.00
Total Non Current Liabilities Net Minority Interest
9,725.00
-1.88%
9,911.00
+7.61%
9,210.00
-1.34%
9,335.00
Liabilities Heldfor Sale Non Current
32.00
0.00
—
—
Long Term Debt And Capital Lease Obligation
8,628.00
-2.62%
8,860.00
+1.25%
8,751.00
-1.73%
8,905.00
Long Term Debt
8,628.00
-2.62%
8,860.00
+1.25%
8,751.00
-1.73%
8,905.00
Non Current Deferred Liabilities
57.00
-22.97%
74.00
+57.45%
47.00
+147.37%
19.00
Non Current Deferred Taxes Liabilities
57.00
-22.97%
74.00
+57.45%
47.00
+147.37%
19.00
Other Non Current Liabilities
1,008.00
+3.17%
977.00
+137.14%
412.00
+0.24%
411.00
Stockholders Equity
752.00
+59.32%
472.00
+774.29%
-70.00
+92.15%
-892.00
Common Stock Equity
752.00
+59.32%
472.00
+774.29%
-70.00
+92.15%
-892.00
Capital Stock
3.00
+0.00%
3.00
+0.00%
3.00
+0.00%
3.00
Common Stock
3.00
+0.00%
3.00
+0.00%
3.00
+0.00%
3.00
Share Issued
260.32
+0.98%
257.80
+0.85%
255.63
+0.49%
254.37
Ordinary Shares Number
260.32
+0.98%
257.80
+0.85%
255.63
+0.49%
254.37
Additional Paid In Capital
167.00
+54.63%
108.00
+332.00%
25.00
0.00
Retained Earnings
1,109.00
+9.80%
1,010.00
+127.99%
443.00
+233.84%
-331.00
Gains Losses Not Affecting Retained Earnings
-527.00
+18.80%
-649.00
-19.96%
-541.00
+4.08%
-564.00
Other Equity Adjustments
-527.00
+18.80%
-649.00
-19.96%
-541.00
+4.08%
-564.00
Total Equity Gross Minority Interest
752.00
+59.32%
472.00
+774.29%
-70.00
+92.15%
-892.00
Total Capitalization
9,380.00
+0.51%
9,332.00
+7.50%
8,681.00
+8.34%
8,013.00
Working Capital
1,962.00
+20.37%
1,630.00
+2.52%
1,590.00
+12.05%
1,419.00
Invested Capital
9,396.00
+0.47%
9,352.00
+7.62%
8,690.00
+8.34%
8,021.00
Total Debt
8,644.00
-2.66%
8,880.00
+1.37%
8,760.00
-1.72%
8,913.00
Net Debt
8,070.00
-1.65%
8,205.00
+1.71%
8,067.00
-1.71%
8,207.00
Net Tangible Assets
-4,531.00
+19.41%
-5,622.00
-7.99%
-5,206.00
+15.27%
-6,144.00
Tangible Book Value
-4,531.00
+19.41%
-5,622.00
-7.99%
-5,206.00
+15.27%
-6,144.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
700.00
-25.45%
939.00
+17.52%
799.00
-6.88%
858.00
Cash Flow From Continuing Operating Activities
700.00
-25.45%
939.00
+17.52%
799.00
-6.88%
858.00
Cash From Discontinued Operating Activities
—
—
0.00
0.00
Net Income From Continuing Operations
187.00
-78.36%
864.00
-15.54%
1,023.00
+11.56%
917.00
Depreciation Amortization Depletion
361.00
+30.32%
277.00
+17.37%
236.00
+11.32%
212.00
Depreciation
156.00
+18.18%
132.00
+10.00%
120.00
+25.00%
96.00
Amortization Cash Flow
205.00
+41.38%
145.00
+25.00%
116.00
+0.00%
116.00
Depreciation And Amortization
361.00
+30.32%
277.00
+17.37%
236.00
+11.32%
212.00
Amortization Of Intangibles
205.00
+41.38%
145.00
+25.00%
116.00
+0.00%
116.00
Other Non Cash Items
43.00
-67.67%
133.00
+241.03%
39.00
-70.68%
133.00
Stock Based Compensation
77.00
-26.67%
105.00
+3.96%
101.00
+34.67%
75.00
Asset Impairment Charge
310.00
0.00
0.00
-100.00%
9.00
Deferred Tax
63.00
+139.38%
-160.00
+67.01%
-485.00
-2594.44%
-18.00
Deferred Income Tax
63.00
+139.38%
-160.00
+67.01%
-485.00
-2594.44%
-18.00
Operating Gains Losses
-94.00
-4600.00%
-2.00
-105.00%
40.00
+322.22%
-18.00
Net Foreign Currency Exchange Gain Loss
-21.00
-950.00%
-2.00
-105.00%
40.00
+322.22%
-18.00
Change In Working Capital
-247.00
+11.15%
-278.00
-79.35%
-155.00
+65.71%
-452.00
Change In Receivables
79.00
-79.37%
383.00
+280.66%
-212.00
-72.36%
-123.00
Changes In Account Receivables
79.00
-79.37%
383.00
+280.66%
-212.00
-72.36%
-123.00
Change In Inventory
-13.00
+90.08%
-131.00
+43.04%
-230.00
-4.55%
-220.00
Change In Payables And Accrued Expense
-420.00
-30.03%
-323.00
-214.95%
281.00
+584.48%
-58.00
Change In Accrued Expense
-142.00
-40.59%
-101.00
-199.02%
102.00
-40.70%
172.00
Change In Payable
-278.00
-25.23%
-222.00
-224.02%
179.00
+177.83%
-230.00
Change In Account Payable
-217.00
-38.22%
-157.00
-196.32%
163.00
+168.78%
-237.00
Change In Other Working Capital
139.00
+379.31%
29.00
+81.25%
16.00
+300.00%
-8.00
Change In Other Current Assets
-32.00
+86.44%
-236.00
-2260.00%
-10.00
+76.74%
-43.00
Investing Cash Flow
-390.00
+23.98%
-513.00
-97.31%
-260.00
+38.10%
-420.00
Cash Flow From Continuing Investing Activities
-390.00
+23.98%
-513.00
-97.31%
-260.00
+38.10%
-420.00
Cash From Discontinued Investing Activities
—
—
0.00
0.00
Net PPE Purchase And Sale
1.00
-75.00%
4.00
+300.00%
1.00
-85.71%
7.00
Sale Of PPE
1.00
-75.00%
4.00
+300.00%
1.00
-85.71%
7.00
Capital Expenditure
-316.00
+9.97%
-351.00
-34.48%
-261.00
+38.88%
-427.00
Capital Expenditure Reported
-162.00
+7.43%
-175.00
+30.28%
-251.00
-28.06%
-196.00
Net Business Purchase And Sale
-75.00
+54.82%
-166.00
0.00
0.00
Purchase Of Business
-75.00
+54.82%
-166.00
0.00
0.00
Net Intangibles Purchase And Sale
-154.00
+12.50%
-176.00
-1660.00%
-10.00
+95.67%
-231.00
Purchase Of Intangibles
-154.00
+12.50%
-176.00
-1660.00%
-10.00
+95.67%
-231.00
Financing Cash Flow
-561.00
-52.45%
-368.00
+35.33%
-569.00
-31.41%
-433.00
Cash Flow From Continuing Financing Activities
-561.00
-52.45%
-368.00
+35.33%
-569.00
-31.41%
-433.00
Net Issuance Payments Of Debt
-458.00
-4063.64%
-11.00
+95.74%
-258.00
-138.89%
-108.00
Issuance Of Debt
1,055.00
-11.05%
1,186.00
+1382.50%
80.00
0.00
Repayment Of Debt
-1,513.00
-26.40%
-1,197.00
-254.14%
-338.00
-212.96%
-108.00
Long Term Debt Issuance
1,055.00
-11.05%
1,186.00
+1382.50%
80.00
0.00
Long Term Debt Payments
-1,513.00
-26.40%
-1,197.00
-254.14%
-338.00
-212.96%
-108.00
Net Long Term Debt Issuance
-458.00
-4063.64%
-11.00
+95.74%
-258.00
-138.89%
-108.00
Short Term Debt Issuance
—
—
—
0.00
Short Term Debt Payments
—
—
0.00
0.00
Net Short Term Debt Issuance
—
—
0.00
0.00
Common Stock Dividend Paid
-88.00
+70.37%
-297.00
-1.02%
-294.00
-1.38%
-290.00
Cash Dividends Paid
-88.00
+70.37%
-297.00
-1.02%
-294.00
-1.38%
-290.00
Net Other Financing Charges
-15.00
+75.00%
-60.00
-252.94%
-17.00
+51.43%
-35.00
Changes In Cash
-251.00
-532.76%
58.00
+293.33%
-30.00
-700.00%
5.00
Effect Of Exchange Rate Changes
150.00
+297.37%
-76.00
-547.06%
17.00
+147.22%
-36.00
Beginning Cash Position
675.00
-2.60%
693.00
-1.84%
706.00
-4.21%
737.00
End Cash Position
574.00
-14.96%
675.00
-2.60%
693.00
-1.84%
706.00
Free Cash Flow
384.00
-34.69%
588.00
+9.29%
538.00
+24.83%
431.00
Change In Income Tax Payable
-61.00
+6.15%
-65.00
-506.25%
16.00
+128.57%
7.00
Change In Tax Payable
-61.00
+6.15%
-65.00
-506.25%
16.00
+128.57%
7.00
Other Cash Adjustment Outside Changein Cash
—
—
0.00
0.00
Cash From Discontinued Financing Activities
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category